Belfast Health and Social Care Trust
caring supporting improving together

FOI/38582

30 October 2026

Alzheimer's Disease

1. **I would be grateful if you could send the most recent planning document(s) for the diagnosis and treatment of Alzheimer's Disease, whether these are from the Health and Social Care Trust, Integrated Care Board (ICB), or the region. I am particularly interested in planning documents that cover lumbar punctures (CSF) and Blood Biomarker testing.**

   The information requested is exempt under Section 21 of the Freedom of Information Act 2000 as it is already publicly available and can be accessed via the Trust's Disclosure Log: 37457 Diagnosis of Alzheimers Disease

2. **To what extent are there plans for service improvement of diagnosing Alzheimer's Disease?**

	Yes / No
Implementation of plans has started	
A plan exists and implementation has not started	
A plan is being developed	
There is no plan	
Other – please state	

   The information requested is exempt under Section 21 of the Freedom of Information Act 2000 as it is already publicly available and can be accessed via the Trust's Disclosure Log: 37457 Diagnosis of Alzheimers Disease

3. **Are the plans for service improvement of diagnosing Alzheimer's Disease related to:**

	Yes / No
Cognitive assessment services	
Biomarker services	
None / neither	

30 October 2026

The information requested is exempt under Section 21 of the Freedom of Information Act 2000 as it is already publicly available and can be accessed via the Trust's Disclosure Log: 37457 Diagnosis of Alzheimers Disease

4. **Which of the following services does the Health and Social Care Trust have in place in preparation for increased service delivery for Alzheimer's Disease?**

	Related to administration of lumbar punctures Yes / No	Related to Blood Biomarker testing Yes / No
Budget		
People		
Training		
Clinic space / capacity		
Governance arrangements		

The information requested is exempt under Section 21 of the Freedom of Information Act 2000 as it is already publicly available and can be accessed via the Trust's Disclosure Log: 37457 Diagnosis of Alzheimers Disease

5. **How many lumbar puncture procedures to test for Alzheimer's Disease were performed in the last three-month period for which data are available?**

	Number of procedures
Number of lumbar punctures	5

6. **Please provide the number of BBM tests for Alzheimer's Disease conducted over the last three-months, regardless of whether they were carried out within your organisation or sent to an external pathology laboratory.**

	Number of tests TOTAL	Number of tests NHS patients	Number of tests Private Sector
Number of Blood Biomarker tests	0	0	0

30 October 2026

7. **Which of the following biomarker tests were used to detect Alzheimer's Disease?**

	Yes / No
pTau181 immunoassay tests	
pTau217 immunoassay tests	

The information requested is exempt under Section 21 of the Freedom of Information Act 2000 as it is already publicly available and can be accessed via the Trust's Disclosure Log: 37457 Diagnosis of Alzheimers Disease

8. **Please provide a list of the full names of other Trusts or other organisations, to which the Trust refers samples for pTau181 and pTau217 immunoassay testing for Alzheimer's Disease?**

Full name of Trust or organisation(s)

The information requested is exempt under Section 21 of the Freedom of Information Act 2000 as it is already publicly available and can be accessed via the Trust's Disclosure Log: 37457 Diagnosis of Alzheimers Disease

9. **How many pTau181 immunoassay tests were conducted to test for Alzheimer's Disease in the last three-months?**

	Number of tests TOTAL	Number of tests NHS patients	Number of tests Private Sector
Number of pTau181 tests	5 CSF	5 CSF	0

10. **Is pTau181 testing for Alzheimer's Disease linked to, or conducted in conjunction with, clinical trials?**

	Yes / No
pTau181 Testing associated with clinical trial activity	

The information requested is exempt under Section 21 of the Freedom of Information Act 2000 as it is already publicly available and can be accessed via the Trust's Disclosure Log: 37457 Diagnosis of Alzheimers Disease

30 October 2026

11. How many pTau181 immunoassay tests were conducted for Alzheimer's Disease as part of a clinical trial?

Number of pTau181 tests	0

12. How many pTau217 immunoassay tests were conducted to test for Alzheimer's Disease in the last three-months?

	Number of tests TOTAL	Number of tests NHS patients	Number of tests Private Sector
Number of pTau217 tests	0	0	0

13. Is pTau217 testing for Alzheimer's Disease linked to, or conducted in conjunction with, clinical trials?

	Yes / No
pTau217 Testing associated with clinical trial activity	

The information requested is exempt under Section 21 of the Freedom of Information Act 2000 as it is already publicly available and can be accessed via the Trust's Disclosure Log: 37457 Diagnosis of Alzheimers Disease

14. How many pTau217 immunoassay tests were conducted for Alzheimer's Disease as part of a clinical trial?

Number of pTau217 tests	0